Coronary Heart DiseaseTechCRNCT04862351
Effectiveness of TechCR Among CHD Patients
A study testing exercise training for TechCR, audio/video conference and educational video in people with Coronary Heart Disease, run by Chinese University of Hong Kong at 1 site in Malaysia.
Trial summary
During this ongoing pandemic, there is a crucial need for innovative approaches to deliver CR programmes other than frequent face-to-face sessions at the centre-based CR to reduce the number of times people come close in contact with others or gathering in large groups. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Coronary Heart Disease
- What is being tested?
- exercise training for TechCR, audio/video conference and educational video
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 160 participants
- Where
- 1 siteMalaysia
- Study dates
- 26 Feb 2021to 31 Oct 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- adults ≥ 18 years old;
- patients with documented acute myocardial infarction, treated with thrombolysis, angioplasty or revascularisation surgery;
- patients who own a mobile phone with internet access;
- patients who have at least completion of primary school education;
- understand English or Malay language;
- patients who will return home for living after hospital discharge;
- patients who are medically stable and referred to CR programme and able to give informed consent to participate in this study.
Who cannot join
- patients who are participating in other studies;
- patients who will undergo any repeat cardiac or other procedure in next 12 months;
- patients with comorbidities such as dementia, impaired hearing or vision or psychiatric illness which may affect the ability to participate in the CR programme;
- patients with pre-existing mobility problems which prevent them from exercising
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effectiveness of Technology-assisted Interventions in Hybrid Cardiac Rehabilitation (TechCR) Among Coronary Heart Disease Patients
During this ongoing pandemic, there is a crucial need for innovative approaches to deliver CR programmes other than frequent face-to-face sessions at the centre-based CR to reduce the number of times people come close in contact with others or gathering in large groups. This is a single setting, 2-arm parallel randomised clinical trial which aims to examine the effects of technology-assisted interventions in hybrid cardiac rehabilitation (TecHCR) among the coronary heart disease patients. Eligible participants will be randomly assigned into either intervention group (IG) or control group (CG) in 1:1 ratio using the computerised permuted blocks, alternating block sizes of 4 or 6. All participants will be followed up for three months and six months with data collection at baseline, (T0), three-month (T1) and six-month (T2) time points.
Read the detailed description
In recent years, CR delivery platforms and approaches have been changing as technology has become an integral part of our daily lives. Some of the barriers to CR may be able to be tackled with the advancement of technology, as it provides an alternative to the traditional centre-based CR through virtual consultations and remote monitoring that may eliminate the hassle of face-to-face consultations, work and time conflicts. During this ongoing pandemic, there is a crucial need for innovative approaches to deliver CR programmes other than frequent face-to-face sessions at the centre-based CR to reduce the number of times people come close in contact with others or gathering in large groups.
The overall aim of this proposed study is to examine the effects of technology-assisted interventions in hybrid cardiac rehabilitation (TecHCR) among the coronary heart disease patients. The objectives are as followings:
- to determine the effects of TecHCR on self-efficacy related to exercise;
- to determine the effects of TecHCR on health promoting behaviours;
- to determine the effects of TecHCR in adherence;
- to determine the effects of TecHCR in exercise capacity;
- to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol, systolic blood pressure, diastolic blood pressure, body mass index and waist circumference;
- to determine the effects of TecHCR anxiety and depression.
With the attrition rate of 20%, a total of 160 eligible participants with 80 per group will be recruited. The control group receives usual care including outpatient medical follow-up with the cardiologists and dietician counselling before hospital discharge. Then, the participants will have their first follow-up by the physicians in cardiac rehabilitation clinic and followed by monthly follow-up. Subsequently, they will have weekly, centre-based supervised exercise training by physiotherapist and follow-up with occupational therapist for 12 weeks. In addition of the usual care of outpatient medical follow-ups and dietary education, the intervention group will receive 3 times supervised exercise in the centre, weekly upload of CR education (audio-visual video) on WhatsApp for six weeks (Week 1 to Week 6). The prescribed exercise will then be continued at home with a pedometer as the "cue to action" to be worn by the participant; he or she will be required to upload the data daily to the web app on the smartphone. Participants will also receive a weekly audio/video-conferencing follow-up (Week 1 to Week 12). The outcome measures include Socio-demographic and Clinical Data, Bandura's exercise self efficacy scale (ESE), Health Promoting Lifestyle Profile II (HPLP II), adherence referring to the attendance to 12 weeks (supervised exercise training) for CG, and attendance (3 times supervised exercise training) and upload of exercise data (for 9 weeks) to web app for IG; and 12-week assessment for both groups, exercise capacity by Exercise Stress Test measuring the metabolic equivalents METs) and Hospital Anxiety and Depression Scale (HADS). The data entry and analysis will be performed using the IBM Social Package Statistical Software (SPSS) version 26.0 with a p value < 0.05 will be consider significant of the result.
- Conditions
- Coronary Heart Disease
- Being tested
- exercise training for TechCR, audio/video conference, educational video, Daily log, exercise training for centre-based
- Keywords
- technology-assisted interventions, hybrid cardiac rehabilitation, coronary heart disease
- Medical subject headings
- Coronary Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
exercise training for TechCRBehavioural
3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic
audio/video conferenceBehavioural
weekly audio/video conference
educational videoBehavioural
weekly for 6 weeks, duration of video about 10-15 minutes
Daily logBehavioural
daily dietary and exercise log
exercise training for centre-basedBehavioural
6 times of supervised exercise training
| Study group | Role | What they receive |
|---|---|---|
| TecHCR | Experimental | 12 weeks Hybrid between supervised exercise training and video call sessions Educational videos Dietary and exercise log Receives: Behavioral: exercise training for TechCR; Behavioral: audio/video conference; Behavioral: educational video; Behavioral: Daily log |
| Centre-based | Other | 12 weeks usual care provided by the centre-based, outpatient cardiac rehabilitation clinic Dietary and exercise log Receives: Behavioral: Daily log; Behavioral: exercise training for centre-based |
What is being measured
The primary outcome is the main question the study is designed to answer.
self-efficacy related to exercise (Bandura's Exercise Self-efficacy)
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise before intervention (baseline)
Measured: Baseline (T0) - at 0 week, before initiation of interventions
self-efficacy related to exercise (Bandura's Exercise Self-efficacy)
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise post intervention (at 3-month)
Measured: post intervention (T1) - at 12 weeks after initiation of interventions
self-efficacy related to exercise (Bandura's Exercise Self-efficacy)
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise 3-month post intervention (T2) (at 6 month)
Measured: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Secondary outcomes (18)
behavioural outcomes (Health-promoting Lifestyle Profile II)
Using Health-promoting lifestyle Profile II to determine the effects of TecHCR on health promoting behaviours
Measured: Baseline (T0) - at 0 week, before initiation of interventions
behavioural outcomes (Health-promoting Lifestyle Profile II)
Using Health-promoting lifestyle Profile II to determine the effects of TecHCR on health promoting behaviours
Measured: post intervention (T1) - at 12 weeks after initiation of interventions
behavioural outcomes (Health-promoting Lifestyle Profile II)
Using Health-promoting lifestyle Profile II to determine the effects of TecHCR on health promoting behaviours
Measured: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
psychological outcomes (Hospital Anxiety and Depression Scale)
Using Hospital Anxiety and Depression Scale to determine the effects of TecHCR on anxiety and depression
Measured: Baseline (T0) - at 0 week, before initiation of interventions
psychological outcomes (Hospital Anxiety and Depression Scale)
Using Hospital Anxiety and Depression Scale to determine the effects of TecHCR on anxiety and depression
Measured: post intervention (T1) - at 12 weeks after initiation of interventions
psychological outcomes (Hospital Anxiety and Depression Scale)
Using Hospital Anxiety and Depression Scale to determine the effects of TecHCR on anxiety and depression
Measured: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (from laboratory blood test result)
to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (mmol/L)
Measured: Baseline (T0) - at 0 week, before initiation of interventions
fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (from laboratory blood test result)
to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (mmol/L)
Measured: post intervention (T1) - at 12 weeks after initiation of interventions
fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (from laboratory blood test result)
to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (mmol/L)
Measured: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
systolic and diastolic blood pressure (using blood pressure monitoring device)
to determine the effects of TecHCR on systolic and diastolic blood pressure
Measured: Baseline (T0) - at 0 week, before initiation of interventions
systolic and diastolic blood pressure (using blood pressure monitoring device)
to determine the effects of TecHCR on systolic and diastolic blood pressure
Measured: post intervention (T1) - at 12 weeks after initiation of interventions
systolic and diastolic blood pressure (using blood pressure monitoring device)
to determine the effects of TecHCR on systolic and diastolic blood pressure
Measured: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Body Mass Index (BMI) (weight in kilogrammes*height in metres^2)
to determine the effects of TecHCR on BMI
Measured: Baseline (T0) - at 0 week, before initiation of interventions
Body Mass Index (BMI) (weight in kilogrammes*height in metres^2)
to determine the effects of TecHCR on BMI
Measured: post intervention (T1) - at 12 weeks after initiation of interventions
Body Mass Index (BMI) (weight in kilogrammes*height in metres^2)
to determine the effects of TecHCR on BMI
Measured: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Waist circumference (measured by measuring tape in centimetres)
to determine the effects of TecHCR on waist circumference
Measured: Baseline (T0) - at 0 week, before initiation of interventions
Waist circumference (measured by measuring tape in centimetres)
to determine the effects of TecHCR on waist circumference
Measured: post intervention (T1) - at 12 weeks after initiation of interventions
Waist circumference (measured by measuring tape in centimetres)
to determine the effects of TecHCR on waist circumference
Measured: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Apr 2021
- Study start26 Feb 2021
- Primary completion31 Oct 2023
- Study completion31 Oct 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Coronary Heart DiseaseStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The eligible participants will be randomly assigned into either intervention group (IG) or control group (CG) in 1:1 ratio using the computerised permuted blocks, alternating block sizes of 4 or 6. Once the eligible participants have consented to participate and the baseline data is collected, they will be given an opaque sealed envelope prepared by an independent statistician (not involved in the research) with assignment information and group allocation specified in the envelope. According to Polit and Beck (2017), the risk of selection bias can be reduced through allocation concealment by shielding the researcher from knowing the next group allocation of an individual.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 160 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mei Sin CHONG, Chinese University of Hong Kong
- Investigators
- Mei Sin Chong, Principal investigator, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04862351
- Sponsor's protocol ID
- 2020.621
- Acronym
- TechCR
- Status last verified
- Apr 2024
- First submitted
- 7 Apr 2021
- Last updated
- 17 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Chong MS, Sit JWH, Choi KC, Suhaimi A, Jiang Y, Chair SY. The Effects of a Technology-Assisted Hybrid Cardiac Rehabilitation (TecHCR) Program for Adults With Coronary Heart Disease: A Randomized Controlled Trial. Worldviews Evid Based Nurs. 2025 Dec;22(6):e70092. doi: 10.1111/wvn.70092.
PubMed 41457512Chong MS, Sit JWH, Choi KC, Suhaimi A, Chair SY. A Theory-Based, Technology-Assisted Intervention in a Hybrid Cardiac Rehabilitation Program for Patients with Coronary Heart Disease: A Feasibility Study. Asian Nurs Res (Korean Soc Nurs Sci). 2023 Aug;17(3):180-190. doi: 10.1016/j.anr.2023.06.004. Epub 2023 Jun 22.
PubMed 37355035
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Technology-assisted Interventions in Hybrid Cardiac Rehabilitation (TechCR) Among Coronary Heart Disease Patients
- ClinicalTrials.gov ID
- NCT04862351
- Acronym / sponsor ID
- TechCR / 2020.621
- Conditions
- Coronary Heart Disease
- Keywords
- technology-assisted interventions, hybrid cardiac rehabilitation, coronary heart disease
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 160 participants (actual)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 26 Feb 2021 (actual)
- Primary completion
- 31 Oct 2023 (actual)
- Study completion
- 31 Oct 2023 (actual)
- First posted
- 28 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
During this ongoing pandemic, there is a crucial need for innovative approaches to deliver CR programmes other than frequent face-to-face sessions at the centre-based CR to reduce the number of times people come close in contact with others or gathering in large groups. This is a single setting, 2-arm parallel randomised clinical trial which aims to examine the effects of technology-assisted interventions in hybrid cardiac rehabilitation (TecHCR) among the coronary heart disease patients. Eligible participants will be randomly assigned into either intervention group (IG) or control group (CG) in 1:1 ratio using the computerised permuted blocks, alternating block sizes of 4 or 6. All participants will be followed up for three months and six months with data collection at baseline, (T0), three-month (T1) and six-month (T2) time points.
Detailed description
In recent years, CR delivery platforms and approaches have been changing as technology has become an integral part of our daily lives. Some of the barriers to CR may be able to be tackled with the advancement of technology, as it provides an alternative to the traditional centre-based CR through virtual consultations and remote monitoring that may eliminate the hassle of face-to-face consultations, work and time conflicts. During this ongoing pandemic, there is a crucial need for innovative approaches to deliver CR programmes other than frequent face-to-face sessions at the centre-based CR to reduce the number of times people come close in contact with others or gathering in large groups.
The overall aim of this proposed study is to examine the effects of technology-assisted interventions in hybrid cardiac rehabilitation (TecHCR) among the coronary heart disease patients. The objectives are as followings:
- to determine the effects of TecHCR on self-efficacy related to exercise;
- to determine the effects of TecHCR on health promoting behaviours;
- to determine the effects of TecHCR in adherence;
- to determine the effects of TecHCR in exercise capacity;
- to determine the effects of TecHCR on fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol, systolic blood pressure, diastolic blood pressure, body mass index and waist circumference;
- to determine the effects of TecHCR anxiety and depression.
With the attrition rate of 20%, a total of 160 eligible participants with 80 per group will be recruited. The control group receives usual care including outpatient medical follow-up with the cardiologists and dietician counselling before hospital discharge. Then, the participants will have their first follow-up by the physicians in cardiac rehabilitation clinic and followed by monthly follow-up. Subsequently, they will have weekly, centre-based supervised exercise training by physiotherapist and follow-up with occupational therapist for 12 weeks. In addition of the usual care of outpatient medical follow-ups and dietary education, the intervention group will receive 3 times supervised exercise in the centre, weekly upload of CR education (audio-visual video) on WhatsApp for six weeks (Week 1 to Week 6). The prescribed exercise will then be continued at home with a pedometer as the "cue to action" to be worn by the participant; he or she will be required to upload the data daily to the web app on the smartphone. Participants will also receive a weekly audio/video-conferencing follow-up (Week 1 to Week 12). The outcome measures include Socio-demographic and Clinical Data, Bandura's exercise self efficacy scale (ESE), Health Promoting Lifestyle Profile II (HPLP II), adherence referring to the attendance to 12 weeks (supervised exercise training) for CG, and attendance (3 times supervised exercise training) and upload of exercise data (for 9 weeks) to web app for IG; and 12-week assessment for both groups, exercise capacity by Exercise Stress Test measuring the metabolic equivalents METs) and Hospital Anxiety and Depression Scale (HADS). The data entry and analysis will be performed using the IBM Social Package Statistical Software (SPSS) version 26.0 with a p value < 0.05 will be consider significant of the result.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- The eligible participants will be randomly assigned into either intervention group (IG) or control group (CG) in 1:1 ratio using the computerised permuted blocks, alternating block sizes of 4 or 6. Once the eligible participants have consented to participate and the baseline data is collected, they will be given an opaque sealed envelope prepared by an independent statistician (not involved in the research) with assignment information and group allocation specified in the envelope. According to Polit and Beck (2017), the risk of selection bias can be reduced through allocation concealment by shielding the researcher from knowing the next group allocation of an individual.
| Arm | Type | Receives |
|---|---|---|
| TecHCR | Experimental | Behavioral: exercise training for TechCR, Behavioral: audio/video conference, Behavioral: educational video, Behavioral: Daily log12 weeks Hybrid between supervised exercise training and video call sessions Educational videos Dietary and exercise log |
| Centre-based | Other | Behavioral: Daily log, Behavioral: exercise training for centre-based12 weeks usual care provided by the centre-based, outpatient cardiac rehabilitation clinic Dietary and exercise log |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- adults ≥ 18 years old;
- patients with documented acute myocardial infarction, treated with thrombolysis, angioplasty or revascularisation surgery;
- patients who own a mobile phone with internet access;
- patients who have at least completion of primary school education;
- understand English or Malay language;
Key exclusion criteria (4 listed)
- patients who are participating in other studies;
- patients who will undergo any repeat cardiac or other procedure in next 12 months;
- patients with comorbidities such as dementia, impaired hearing or vision or psychiatric illness which may affect the ability to participate in the CR programme;
- patients with pre-existing mobility problems which prevent them from exercising
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| exercise training for TechCR3 times of supervised exercise training at the centre-based, outpatient cardiac rehabilitation clinic | Behavioural | TecHCR |
| audio/video conferenceweekly audio/video conference | Behavioural | TecHCR |
| educational videoweekly for 6 weeks, duration of video about 10-15 minutes | Behavioural | TecHCR |
| Daily logdaily dietary and exercise log | Behavioural | Centre-based, TecHCR |
| exercise training for centre-based6 times of supervised exercise training | Behavioural | Centre-based |
Primary outcome
self-efficacy related to exercise (Bandura's Exercise Self-efficacy)
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise before intervention (baseline)
self-efficacy related to exercise (Bandura's Exercise Self-efficacy)
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise post intervention (at 3-month)
self-efficacy related to exercise (Bandura's Exercise Self-efficacy)
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Using Bandura's Exercise Self-efficacy to determine the effects of TecHCR on self-efficacy related to exercise 3-month post intervention (T2) (at 6 month)
18 secondary outcomes
behavioural outcomes (Health-promoting Lifestyle Profile II)
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
behavioural outcomes (Health-promoting Lifestyle Profile II)
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
behavioural outcomes (Health-promoting Lifestyle Profile II)
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
psychological outcomes (Hospital Anxiety and Depression Scale)
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
psychological outcomes (Hospital Anxiety and Depression Scale)
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
psychological outcomes (Hospital Anxiety and Depression Scale)
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (from laboratory blood test result)
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (from laboratory blood test result)
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
fasting low density lipoprotein (LDL), high density lipoprotein (HDL), total cholesterol (from laboratory blood test result)
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
systolic and diastolic blood pressure (using blood pressure monitoring device)
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
systolic and diastolic blood pressure (using blood pressure monitoring device)
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
systolic and diastolic blood pressure (using blood pressure monitoring device)
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Body Mass Index (BMI) (weight in kilogrammes*height in metres^2)
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
Body Mass Index (BMI) (weight in kilogrammes*height in metres^2)
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
Body Mass Index (BMI) (weight in kilogrammes*height in metres^2)
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Waist circumference (measured by measuring tape in centimetres)
Time frame: Baseline (T0) - at 0 week, before initiation of interventions
Waist circumference (measured by measuring tape in centimetres)
Time frame: post intervention (T1) - at 12 weeks after initiation of interventions
Waist circumference (measured by measuring tape in centimetres)
Time frame: 6-month post intervention (T2) - at 36 weeks after initiation of interventions
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2024.
- Derived from this study: PubMed 41457512Chong MS, Sit JWH, Choi KC, Suhaimi A, Jiang Y, Chair SY. The Effects of a Technology-Assisted Hybrid Cardiac Rehabilitation (TecHCR) Program for Adults With Coronary Heart Disease: A Randomized Controlled Trial. Worldviews Evid Based Nurs. 2025 Dec;22(6):e70092. doi: 10.1111/wvn.70092.
- Derived from this study: PubMed 37355035Chong MS, Sit JWH, Choi KC, Suhaimi A, Chair SY. A Theory-Based, Technology-Assisted Intervention in a Hybrid Cardiac Rehabilitation Program for Patients with Coronary Heart Disease: A Feasibility Study. Asian Nurs Res (Korean Soc Nurs Sci). 2023 Aug;17(3):180-190. doi: 10.1016/j.anr.2023.06.004. Epub 2023 Jun 22.
- Individual participant dataSharing planned: No
Related trials for Coronary Heart Disease
RecruitingObservational study
Atrial Fibrillation Patients Treated With Catheter Ablation
Atrial Fibrillation, Atrial Fibrillation Recurrent
RecruitingObservational study
An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias
Arrhythmias, Cardiac
Not yet recruitingObservational study
Heart and Brain Blood Flow in Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA)
Recruiting
ELEVATE-HFpEF Clinical Study
Heart Failure With Preserved Ejection Fraction (HFpEF)
Not yet recruiting
Effect of Double-Tap Optimization on Valve Expansion and Hemodynamics in Balloon-expandable Transcatheter Aortic Valve Implantation: A Randomized Clinical Trial (DO-OPT TAVI Trial)
Severe Aortic Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mei Sin Chong principal investigator
Chinese University of Hong Kong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing exercise training for TechCR, audio/video conference and educational video in people with Coronary Heart Disease, run by Chinese University of Hong Kong at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
self-efficacy related to exercise (Bandura's Exercise Self-efficacy) (time frame: Baseline (T0) - at 0 week, before initiation of interventions). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04862351, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2024.